ECSP056175A - Heterociclos de nitrógeno n-acilo como ligandos de receptores activados por el proliferador de peroxisoma - Google Patents

Heterociclos de nitrógeno n-acilo como ligandos de receptores activados por el proliferador de peroxisoma

Info

Publication number
ECSP056175A
ECSP056175A EC2005006175A ECSP056175A ECSP056175A EC SP056175 A ECSP056175 A EC SP056175A EC 2005006175 A EC2005006175 A EC 2005006175A EC SP056175 A ECSP056175 A EC SP056175A EC SP056175 A ECSP056175 A EC SP056175A
Authority
EC
Ecuador
Prior art keywords
diseases
peroxisome proliferator
conditions
legands
acilo
Prior art date
Application number
EC2005006175A
Other languages
English (en)
Inventor
Gary Michael Ksander
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33476920&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP056175(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP056175A publication Critical patent/ECSP056175A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)

Abstract

Los compuestos de la fórmula (I) proporcionan agentes farmacológicos que se unen a receptores activados por el proliferador de peroxisoma (PPARs). De acuerdo con lo anterior, los compuestos de la presente invención son útiles para el tratamiento de condiciones mediadas por la actividad del receptor de PPAR en mamíferos. Tales condiciones incluyen dislipidemia, hiperlipidemia, hipercolesteremia, aterosclerosis, hipertrigliceridemia, falla cardiaca, infarto al miocardio, enfermedades vasculares, enfermedades cardiovasculares, hipertensión, obesidad, inflamación, artritis, cáncer, enfermedad de Alzheimer, trastornos de la piel, enfermedades respiratorias, trastornos oftálmicos, enfermedades inflamatorias del intestino, colitis ulcerativa, enfermedad de Crohn, y condiciones donde están implicadas la tolerancia dañada a glucosa, hiperglicemia y resistencia a insulina, tal como diabetes de tipo 1 y de tipo 2, y síndrome X.
EC2005006175A 2003-05-20 2005-11-18 Heterociclos de nitrógeno n-acilo como ligandos de receptores activados por el proliferador de peroxisoma ECSP056175A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US47206703P 2003-05-20 2003-05-20

Publications (1)

Publication Number Publication Date
ECSP056175A true ECSP056175A (es) 2006-04-19

Family

ID=33476920

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2005006175A ECSP056175A (es) 2003-05-20 2005-11-18 Heterociclos de nitrógeno n-acilo como ligandos de receptores activados por el proliferador de peroxisoma

Country Status (26)

Country Link
US (1) US7652061B2 (es)
EP (1) EP1638963B1 (es)
JP (1) JP4637843B2 (es)
KR (2) KR100849747B1 (es)
CN (1) CN1795193B (es)
AR (1) AR044399A1 (es)
AT (1) ATE442365T1 (es)
AU (1) AU2004240754B9 (es)
BR (1) BRPI0410779A (es)
CA (1) CA2525764C (es)
CL (1) CL2004001169A1 (es)
CO (1) CO5650248A2 (es)
DE (1) DE602004023080D1 (es)
EC (1) ECSP056175A (es)
ES (1) ES2331131T3 (es)
IS (1) IS8160A (es)
MA (1) MA27777A1 (es)
MX (1) MXPA05012465A (es)
NO (1) NO20056056L (es)
PE (1) PE20050157A1 (es)
PT (1) PT1638963E (es)
RU (1) RU2374241C2 (es)
TN (1) TNSN05295A1 (es)
TW (1) TW200524918A (es)
WO (1) WO2004103995A1 (es)
ZA (1) ZA200508905B (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0412557A (pt) * 2003-07-28 2006-09-19 Reddys Lab Inc Dr forma de dosagem farmacêutica de eventos cardiovasculares
WO2006002349A1 (en) * 2004-06-24 2006-01-05 Incyte Corporation Amido compounds and their use as pharmaceuticals
NZ551603A (en) 2004-06-24 2010-11-26 Incyte Corp N-substituted piperidines and their use as pharmaceuticals
AR050631A1 (es) * 2004-09-09 2006-11-08 Novartis Ag Combinacion de compuestos organicos
CN102036662B (zh) * 2005-06-27 2013-02-27 新树股份有限公司 利用肉豆蔻衣木脂素预防和治疗ppar介导的疾病的方法
PE20070427A1 (es) 2005-08-30 2007-04-21 Novartis Ag Compuestos derivados de benzimidazoles sustituidos como inhibidores de tirosina quinasas
US20070116756A1 (en) * 2005-11-23 2007-05-24 Dr. Reddy's Laboratories Limited Stable pharmaceutical compositions
KR101456721B1 (ko) 2006-03-31 2014-10-31 노파르티스 아게 신규 화합물
PE20080888A1 (es) 2006-10-18 2008-08-26 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE LA ACIL-TRANSFERASA DE ACIL-CoA-DIACIL-GLICEROL 1 (DGAT1)
PE20110105A1 (es) 2008-07-15 2011-02-25 Novartis Ag Derivados de heteroarilo como inhibidores de dgat1
JP5062097B2 (ja) * 2008-08-21 2012-10-31 富士通株式会社 情報処理装置、情報処理装置の制御方法、および情報処理装置の制御プログラム
US8491927B2 (en) 2009-12-02 2013-07-23 Nimble Epitech, Llc Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
EP2625172B1 (en) 2010-10-07 2016-12-07 Novartis AG New crystalline forms of the sodium salt of (4- {4- [5- ( 6 - trifluoromethyl - pyridin- 3 - ylamino ) - pyridin- 2 -yl]-phenyl} - cyclohexyl) -acetic acid
EP2663561B1 (en) 2011-01-13 2016-03-16 Novartis AG Novel heterocyclic derivatives and their use in the treatment of neurological disorders
AU2012206527A1 (en) 2011-01-13 2013-08-01 Novartis Ag BACE-2 inhibitors for the treatment of metabolic disorders
US8614195B2 (en) 2011-04-14 2013-12-24 Novartis Ag Glycoside derivatives and uses thereof
US8722633B2 (en) 2011-04-14 2014-05-13 Novartis Ag Glycoside derivatives and uses thereof
KR20140048235A (ko) 2011-07-08 2014-04-23 노파르티스 아게 신규 트리플루오로메틸-옥사디아졸 유도체 및 질환의 치료에서의 그의 용도
UY34278A (es) 2011-08-25 2013-04-05 Novartis Ag Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades
EP2758403B1 (en) 2011-09-21 2016-04-27 Inception Orion, Inc. Tricyclic compounds useful as neurogenic and neuroprotective agents
JP2014532066A (ja) 2011-10-13 2014-12-04 ノバルティス アーゲー オキサジン誘導体および神経障害の処置におけるその使用
EP2785713B1 (en) 2011-11-28 2016-09-07 Novartis AG Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9108956B2 (en) 2012-04-27 2015-08-18 Novartis Ag Cyclic ether DGAT1 inhibitorscyclic ether DGAT1 inhibitors
CA2870336A1 (en) 2012-04-27 2013-10-31 Novartis Ag Cyclic bridgehead ether dgat1 inhibitors
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3052485B1 (en) 2013-10-04 2021-07-28 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP4066834A1 (en) 2014-03-19 2022-10-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
US20170204149A1 (en) 2014-06-23 2017-07-20 Novartis Ag Hsa-gdf-15 fusion polypeptide and use thereof
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
EP3350183A1 (en) 2015-09-14 2018-07-25 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
JP6946304B2 (ja) 2015-12-22 2021-10-06 ノバルティス アーゲー 増殖分化因子１５（ｇｄｆ−１５）を使用して代謝障害を処置するまたは軽快させる方法
US10759806B2 (en) 2016-03-17 2020-09-01 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3437651A1 (en) 2017-08-03 2019-02-06 Université de Strasbourg Peptides for treatment and prevention of nonalcoholic fatty liver disease
CN111432829B (zh) 2017-12-14 2023-07-14 斯特拉斯堡大学 用于治疗和预防非酒精性脂肪肝病和纤维化的肽
JP2022509184A (ja) 2018-11-27 2022-01-20 ノバルティス アーゲー 代謝性障害の処置のためのプロタンパク質コンバターゼスブチリシン／ケキシン９型（ｐｃｓｋ９）阻害剤としての環状ペプチド
EP3887363A1 (en) 2018-11-27 2021-10-06 Novartis AG Cyclic pentamer compounds as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorder
UY38485A (es) 2018-11-27 2020-06-30 Novartis Ag Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparación
IL284029B2 (en) 2018-12-21 2023-09-01 Univ Strasbourg Peptides for the treatment and prevention of diabetes and related disorders
WO2022219495A1 (en) 2021-04-12 2022-10-20 Novartis Ag 2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity
TW202333563A (zh) 2021-11-12 2023-09-01 瑞士商諾華公司 用於治療疾病或障礙之二胺基環戊基吡啶衍生物
WO2023152698A1 (en) 2022-02-10 2023-08-17 Novartis Ag 2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5045540A (en) * 1990-05-25 1991-09-03 Warner-Lambert Co. Amino acid derivatives with angiotensin II antagonist properties
PT915088E (pt) * 1997-10-31 2003-01-31 Hoffmann La Roche Derivados de d-prolina
AU4180900A (en) * 1999-04-02 2000-10-23 Du Pont Pharmaceuticals Company Novel amide derivatives as inhibitors of matrix metalloproteinases, tnf-alpha, and aggrecanase
GB0024362D0 (en) * 2000-10-05 2000-11-22 Glaxo Group Ltd Medicaments
US7105556B2 (en) * 2001-05-30 2006-09-12 Bristol-Myers Squibb Company Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method
TW200303742A (en) * 2001-11-21 2003-09-16 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
PT1638963E (pt) 2009-11-18
CO5650248A2 (es) 2006-06-30
MXPA05012465A (es) 2006-01-30
ES2331131T3 (es) 2009-12-22
EP1638963B1 (en) 2009-09-09
IS8160A (is) 2005-11-30
AR044399A1 (es) 2005-09-14
CA2525764A1 (en) 2004-12-02
CN1795193A (zh) 2006-06-28
PE20050157A1 (es) 2005-05-17
KR100909918B1 (ko) 2009-07-29
AU2004240754B9 (en) 2008-10-23
KR20080007519A (ko) 2008-01-21
AU2004240754B2 (en) 2008-09-18
US7652061B2 (en) 2010-01-26
CL2004001169A1 (es) 2005-03-28
JP4637843B2 (ja) 2011-02-23
DE602004023080D1 (de) 2009-10-22
MA27777A1 (fr) 2006-02-01
WO2004103995A1 (en) 2004-12-02
US20060135593A1 (en) 2006-06-22
CA2525764C (en) 2012-07-17
RU2374241C2 (ru) 2009-11-27
JP2007501263A (ja) 2007-01-25
CN1795193B (zh) 2010-08-18
TNSN05295A1 (en) 2007-07-10
KR20060014054A (ko) 2006-02-14
TW200524918A (en) 2005-08-01
EP1638963A1 (en) 2006-03-29
ATE442365T1 (de) 2009-09-15
AU2004240754A1 (en) 2004-12-02
KR100849747B1 (ko) 2008-07-31
NO20056056L (no) 2006-02-17
ZA200508905B (en) 2008-08-27
BRPI0410779A (pt) 2006-06-27
RU2005139525A (ru) 2006-08-10

Similar Documents

Publication Publication Date Title
ECSP056175A (es) Heterociclos de nitrógeno n-acilo como ligandos de receptores activados por el proliferador de peroxisoma
ECSP045103A (es) Compuestos heterociclicos y metodos de uso
BRPI0412380A (pt) compostos de benzenossulfonilamino e composições farmacêuticas que contêm esses compostos
CO2021008089A2 (es) Agonistas de glp-1r y usos de los mismos
MXPA06003055A (es) Compuestos organicos.
MX2015010935A (es) Compuestos biciclicos antidiabeticos.
MX2015001500A (es) Compuestos antidiabeticos triciclicos.
ZA202205346B (en) Glp-1 receptor agonist and use thereof
CY1121423T1 (el) Φαρμακευτικη συνθεση για την αντιμετωπιση ενος μεταβολικου συνδρομου
CL2011001848A1 (es) Compuestos derivados de pirimidina fusionada a un heterociclo de 5 miembros; antagonista del receptor de angiotensina ii, agonista del receptor de proliferador de peroxisomas; composicion farmaceutica; y uso de los compuestos en el tratamiento de enfermedades circulatorias tales como hipertension, enfermedad cardiaca, arteriosclerosis, entre otras.
MX2016015182A (es) Compuestos triciclicos antidiabeticos.
BR112022000027A2 (pt) Compostos agonistas gipr
AR047669A1 (es) Entidad seleccionada entre un compuesto de xantina y un derivado fisiologicamente funcional del mismo, su uso para la fabricacion de un medicamento, formulacion farmaceutica y combinacion de formulaciones que la comprenden y metodo para su preparacion
RU2010120808A (ru) Производное амина, обладающее активностью антагониста npy y5 рецептора, и его применение
CL2008002351A1 (es) Compuestos derivados de 6-triazolopiridazina-sulfanil benzotiazol y bencimidazol; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento del cancer.
EA201171197A1 (ru) Замещенные производные азоантрацена, фармацевтические композиции и способы их применения
ATE546142T1 (de) Salze und polymorphe einer wirkungsvollen antidiabetischen verbindung
BR112019002245A2 (pt) agonistas de receptor acoplado à proteína g
JP2016508506A5 (es)
BRPI0407180A (pt) Composto, composição farmacêutica, métodos para modular um receptor ativado pelo proliferador de peroxissoma, para tratar ou prevenir uma doença ou condição, para diminuir a glicose no sangue em um mamìfero, para tratar ou prevenir diabetes mellitus, doença cardiovascular e sìndrome x em um mamìfero, e, uso de um composto
EA201100910A1 (ru) Лечение воспалительных заболеваний кишечника бета-дефенсинами млекопитающих
EP1948161A4 (en) METHOD OF PREVENTION AND TREATMENT WITH MACELIGNAN OF MEDIA MEDIA BY PPAR
EA201070783A1 (ru) 1,2,4-оксадизольные соединения для лечения аутоиммунных заболеваний
NZ594244A (en) Thiadiazole and oxadiazole derivatives, preparation thereof, and therapeutic use thereof
MX2022015500A (es) Farmaco profilactico y terapeutico para enfermedad de higado graso no alcoholico.